The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized,...

Area of Science:

• Nephrology
• Cardiology
• Oxidative Stress Research

Background:

• Patients with end-stage renal failure experience heightened oxidative stress.
• Cardiovascular mortality is significantly elevated in this patient population.
• The efficacy of antioxidants in preventing cardiovascular events in these patients remains unclear.

Purpose of the Study:

• To investigate the impact of acetylcysteine, an antioxidant, on cardiovascular events in hemodialysis patients.
• To determine if antioxidant therapy can mitigate cardiovascular risks associated with end-stage renal disease.

Main Methods:

• A prospective, randomized, placebo-controlled trial involving 134 hemodialysis patients.
• Patients received either acetylcysteine (600 mg twice daily) or a placebo.
• The primary endpoint was a composite of major adverse cardiovascular events over a median follow-up of 14.5 months.

Main Results:

• A significant reduction in the composite cardiovascular endpoint was observed in the acetylcysteine group (28%) compared to the placebo group (47%).
• The relative risk for the primary endpoint was 0.60 (95% CI, 0.38 to 0.95; P=0.03).
• No significant differences were found in secondary endpoints or total mortality between the groups.

Conclusions:

• Treatment with acetylcysteine (600 mg twice daily) effectively reduces composite cardiovascular endpoints in patients undergoing hemodialysis.
• Acetylcysteine may be a beneficial therapeutic option for managing cardiovascular risk in this vulnerable population.